http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008161337-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92d6219f3192548fa975e9ddac97ba06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate | 2007-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8f2c6c7a463a4f5874b21b718a1024 |
| publicationDate | 2008-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008161337-A1 |
| titleOfInvention | Use of Rifaximin for the Treatment of Chronic Prostatitis |
| abstract | Chronic prostatitis (CP) is a syndrome characterized by pelvic pain in one or more areas (perineum, lower abdominal, testicular and/or penile), urinary frequency, urinary urgency, sexual dysfunction and/or ejaculatory pain. CP type IIIa is the most common type of prostatitis and is defined by having sterile EPS and a leukocyte count greater than 1000/mm 2 . A method of prevention of chronic prostatitis is disclosed that comprises orally administering a composition containing a therapeutically effective amount of rifaximin to a patient exhibiting symptoms of chronic prostatitis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017125011-A |
| priorityDate | 2007-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.